Publikationen in Zusammenarbeit mit Forschern von Dana–Farber Cancer Institute (1)

2016

  1. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

    Annals of Oncology, Vol. 27, pp. vi68